CoChat
Sign Up
Cited by 141

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

The problem of choice: current biologic agents and future prospects in RA

Choy, Ernest H., Kavanaugh, Arthur F., Jones, Simon A.·2013·Nature Reviews Rheumatology
DOI 10.1038/nrrheum.2013.8
Open this paper in CoChat — free account

Abstract

The introduction of biologic agents to clinical practice has had a major bearing on the treatment of patients with chronic inflammatory diseases such as rheumatoid arthritis. These drugs have the potential to improve the outcome of disease and the quality of life for patients. However, clinical criteria alone are inadequate for determining which therapy is most appropriate for an individual patient. Furthermore, why a particular drug is effective in a particular patient, or indeed in any patient, but is ineffective for other individuals, is often unknown. In this Review, we provide an overview of biologic therapies currently available for patients with rheumatoid arthritis, and discuss why certain immunological regulators represent potential targets for intervention. Current agents can be clustered into three major types: cytokine blockers, lymphocyte-targeting agents, and small-molecule inhibitors of signal transduction pathways. We differentiate among the modes of action of each of these types of therapy and consider the challenges associated with their use in clinical practice.

Overview

Integrity signals

Registry

Crossref · 10.1038/nrrheum.2013.8

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 3 references

Research works printed but not linked: 88

  1. Singh, J. A. et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res. 64, 625–639 (2012). · DOI
  2. Smolen, J. S. et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann. Rheum. Dis. 69, 964–975 (2010). · DOI
  3. Singh, J. A. et al. Biologics for rheumatoid arthritis: an overview of Cochrane reviews. Sao Paulo Med. J. 128, 309–310 (2010). · DOI
  4. Smolen, J. S. et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet 374, 210–221 (2009). · DOI
  5. Cohen, S. B. et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 54, 2793–2806 (2006). · DOI
  6. Genovese, M. C. et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor α inhibition. N. Engl. J. Med. 353, 1114–1123 (2005). · DOI
  7. Emery, P. et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann. Rheum. Dis. 67, 1516–1523 (2008). · DOI · Paper page
  8. Molenaar, E. T. et al. Progression of radiologic damage in patients with rheumatoid arthritis in clinical remission. Arthritis Rheum. 50, 36–42 (2004). · DOI
  9. Furst, D. E. et al. Adalimumab, a fully human anti tumor necrosis factor-α monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J. Rheumatol. 30, 2563–71 (2003).
  10. Klareskog, L., Catrina, A. I., Paget, S. Rheumatoid arthritis. Lancet 373, 659–672 (2009). · DOI
  11. Isaacs, J. D. et al. Effect of baseline rheumatoid factor and anti-citrullinated peptide antibody serotype on rituximab clinical response: a meta-analysis. Ann. Rheum. Dis. http://dx.doi.org/10.1136/annrheumdis-2011-201117 · DOI
  12. Bugatti, S. A. et al. Synovial tissue heterogeneity and peripheral blood biomarkers. Curr. Rheumatol. Rep. 13, 440–448 (2011). · DOI
  13. de Hair, M. J. et al. Synovial tissue analysis for the discovery of diagnostic and prognostic biomarkers in patients with early arthritis. J. Rheumatol. 38, 2068–2072 (2011). · DOI
  14. van de Sande, M. G. et al. Evaluating antirheumatic treatments using synovial biopsy: a recommendation for standardization to be used in clinical trials. Ann. Rheum. Dis. 70, 423–427 (2011). · DOI
  15. McInnes, I. B. & O'Dell, J. R. State-of-the-art: rheumatoid arthritis. Ann. Rheum. Dis. 69, 1898–1906 (2010). · DOI
  16. Stranger, B. E., Stahl, E. A. & Raj, T. Progress and promise of genome-wide association studies for human complex trait genetics. Genetics 187, 367–383 (2011). · DOI · Paper page
  17. Feldmann, M., Brennan, F. M., Maini, R. N. Role of cytokines in rheumatoid arthritis. Ann. Rev. Immunol. 14, 397–440 (1996). · DOI
  18. Stahl, E. A. et al. Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. Nat. Gen. 42, 508–514 (2010). · DOI · Paper page
  19. Woodrick, R. S. & Ruderman, E. M. Safety of biologic therapy in rheumatoid arthritis. Nat. Rev. Rheumatol. 7, 639–652 (2011). · DOI
  20. Choy, E. H. & Panayi, G. S. Cytokine pathways and joint inflammation in rheumatoid arthritis. N. Engl. J. Med. 344, 907–916 (2001). · DOI
  21. McInnes, I. B. & Schett, G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat. Rev. Immunol. 7, 429–442 (2007). · DOI
  22. Dayer, J. M. & Choy, E. Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor. Rheumatology 49, 15–24 (2010). · DOI
  23. Kirkham, B. Interleukin-1, immune activation pathways, and different mechanisms in osteoarthritis and rheumatoid arthritis. Ann. Rheum. Dis. 50, 395–400 (1991). · DOI
  24. Carroll, G., Bell, M., Wang, H., Chapman, H. & Mills, J. Antagonism of the IL-6 cytokine subfamily—a potential strategy for more effective therapy in rheumatoid arthritis. Inflamm. Res. 47, 1–7 (1998). · DOI
  25. Busso, N. & So, A. Mechanisms of inflammation in gout. Arthritis Res. Ther. 12, 206 (2010). · DOI
  26. Aaltonen, K. J. et al. Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis. PLoS ONE 7, e30275 (2012). · DOI
  27. Singh, J. A., Beg, S. & Lopez-Olivo, M. A. Tocilizumab for rheumatoid arthritis: a Cochrane systematic review. J. Rheumatol. 38, 10–20 (2011). · DOI
  28. Brennan, F. M., Maini, R. N. & Feldmann, M. TNF α--a pivotal role in rheumatoid arthritis? Br. J. Rheumatol. 31, 293–298 (1992). · DOI
  29. Yokota, S. et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet. 371, 998–1006 (2008). · DOI · Paper page
  30. Silke, J. The regulation of TNF signalling: what a tangled web we weave. Curr. Opin. Immunol. 23, 620–626 (2011). · DOI
  31. Kamimura, D., Ishihara, K. & Hirano, T. IL-6 signal transduction and its physiological roles: the signal orchestration model. Rev. Physiol. Biochem. Pharmacol. 149, 1–38 (2003).
  32. Nowell, M. A. et al. Therapeutic targeting of IL-6 trans signaling counteracts STAT3 control of experimental inflammatory arthritis. J. Immunol. 182, 613–622 (2009). · DOI · Paper page
  33. de Hooge, A. S. et al. Local activation of STAT-1 and STAT-3 in the inflamed synovium during zymosan-induced arthritis: exacerbation of joint inflammation in STAT-1 gene-knockout mice. Arthritis Rheum. 50, 2014–2023 (2004). · DOI
  34. Hayden, M. S. & Ghosh, S. NF-κB, the first quarter-century: remarkable progress and outstanding questions. Genes Dev. 26, 203–234 (2012). · DOI · Paper page
  35. Cheon, H., Yang, J. & Stark, G. R. The functions of signal transducers and activators of transcriptions 1 and 3 as cytokine-inducible proteins. J. Interferon Cytokine Res. 31, 33–40 (2011). · DOI
  36. Jones, S. A., Scheller, J. & Rose-John, S. Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. J. Clin. Invest. 121, 3375–3383 (2011). · DOI
  37. Hsu, B., Sheng, S., Smolen, J. & Weinblatt, M. Results from a 2-part, proof-of-concept, dose-ranging, randomized, double-blind, placebo-controlled, phase 2 study of sirukumab, a human anti-interleukin-6 monoclonal antibody, in active rheumatoid arthritis patients despite methotrexate therapy. Arthritis Rheum. 63 (Suppl.), S1034 (2011).
  38. Hickling, M. et al. Safety and pharmacokinetics of CDP6038, an anti-IL-6 monoclonal antibody, administered by subcutaneous injection and intravenous infusion to healthy male volunteers: a phase 1 study. Ann. Rheum. Dis. 70 (Suppl. 3), 471 (2011).
  39. Mease, P. et al. A phase II, double-blind, randomised, placebo-controlled study of BMS945429 (ALD518) in patients with rheumatoid arthritis with an inadequate response to methotrexate. Ann. Rheum. Dis. 71, 1183–1189 (2012). · DOI
  40. Radin, A. et al. Safety and effects on markers of inflammation of subcutaneously administered regn88/sar153191 (regn88), an interleukin-6 receptor inhibitor, in patients with rheumatoid arthritis: findings from phase 1 studies. Ann. Rheum. Dis. 69 (Suppl. 3), 99 (2010).
  41. Lissilaa, R. et al. Although IL-6 trans-signaling is sufficient to drive local immune responses, classical IL-6 signaling is obligate for the induction of T cell-mediated autoimmunity. J. Immunol. 185, 5512–5521 (2010). · DOI
  42. Richards, P. J. et al. Functional characterization of a soluble gp130 isoform and its therapeutic capacity in an experimental model of inflammatory arthritis. Arthritis Rheum. 54, 1662–1672 (2006). · DOI
  43. Hueber, W. et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci. Transl. Med. 2, 52–72 (2010). · DOI · Paper page
  44. Papp, K. A. et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N. Engl. J. Med. 366, 1181–1189 (2012). · DOI
  45. Gandhi, M. et al. Anti-p40 antibodies ustekinumab and briakinumab: blockade of interleukin-12 and interleukin-23 in the treatment of psoriasis. Semin. Cutan. Med. Surg. 29, 48–52 (2010). · DOI
  46. Hunter, C. A. New IL-12-family members: IL-23 and IL-27, cytokines with divergent functions. Nat. Rev. Immunol. 5, 521–531 (2005). · DOI
  47. Murphy, K. M. & Stockinger, B. Effector T cell plasticity: flexibility in the face of changing circumstances. Nat Immunol. 11, 674–680 (2010). · DOI · Paper page
  48. Mukasa, A. et al. Epigenetic instability of cytokine and transcription factor gene loci underlies plasticity of the T helper 17 cell lineage. Immunity 32, 616–627 (2010). · DOI
  49. Wei, G. et al. Global mapping of H3K4me3 and H3K27me3 reveals specificity and plasticity in lineage fate determination of differentiating CD4+ T cells. Immunity 30, 155–167 (2009). · DOI · Paper page
  50. Zhu, J. & Paul, W. E. CD4+ T cell plasticity—TH2 cells join the crowd. Immunity 32, 11–13 (2010). · DOI
  51. Cornelissen, F. et al. Interleukin-23 is critical for full-blown expression of a non-autoimmune destructive arthritis and regulates interleukin-17A and RORγt in γδ T cells. Arthritis Res. Ther. 11, R194 (2009). · DOI
  52. Cragg, M. S., Walshe, C. A., Ivanov, A. O. & Glennie, M. J. The biology of CD20 and its potential as a target for mAb therapy. Curr. Dir. Autoimmun. 8, 140–174 (2005). · DOI
  53. Edwards, J. C., Leandro, M. J. & Cambridge, G. B lymphocyte depletion in rheumatoid arthritis: targeting of CD20. Curr. Dir. Autoimmun. 8, 175–192 (2005). · DOI
  54. Vos, K. et al. Early effects of rituximab on the synovial cell infiltrate in patients with rheumatoid arthritis. Arthritis Rheum. 56, 772–778 (2007). · DOI
  55. Teng, Y. K. et al. Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment. Arthritis Rheum. 56, 3909–3918 (2007). · DOI
  56. Vital, E. M. et al. Management of nonresponse to rituximab in rheumatoid arthritis: predictors and outcome of re-treatment. Arthritis Rheum. 62, 1273–1279 (2010). · DOI
  57. Dorner, T., Kinnman, N. & Tak, P. P. Targeting B cells in immune-mediated inflammatory disease: a comprehensive review of mechanisms of action and identification of biomarkers. Pharmacol. Ther. 125, 464–475 (2010). · DOI
  58. Kausar, F. et al. Ocrelizumab: a step forward in the evolution of B-cell therapy. Exp. Opin. Biol. Ther. 9, 889–895 (2009). · DOI
  59. Goldenberg, D. M., Morschhauser, F. & Wegener, W. A. Veltuzumab (humanized anti-CD20 monoclonal antibody): characterization, current clinical results, and future prospects. Leuk. Lymphoma. 51, 747–755 (2010). · DOI
  60. Taylor, P. C. et al. Ofatumumab, a fully human anti-CD20 monoclonal antibody, in biological-naive, rheumatoid arthritis patients with an inadequate response to methotrexate: a randomised, double-blind, placebo-controlled clinical trial. Ann. Rheum. Dis. 70, 2119–2125 (2011). · DOI
  61. Dorner, T. & Goldenberg, D. M. Targeting CD22 as a strategy for treating systemic autoimmune diseases. Ther. Clin. Risk Manage. 3, 953–959 (2007).
  62. Tak, P. P. et al. Atacicept in patients with rheumatoid arthritis: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating, single- and repeated-dose study. Arthritis Rheum. 58, 61–72 (2008). · DOI
  63. Cohen, S. B. Updates from B cell trials: efficacy. J. Rheumatol. 77 (Suppl.), 12–17 (2006).
  64. van Vollenhoven, R. F., Kinnman, N., Vincent, E., Wax, S. & Bathon, J. Atacicept in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase II, randomized, placebo-controlled trial. Arthritis Rheum. 63, 1782–1792 (2011). · DOI
  65. Genovese, M. C., Kinnman, N., de La Bourdonnaye, G., Pena Rossi, C. & Tak, P. P. Atacicept in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor antagonist therapy: results of a phase II, randomized, placebo-controlled, dose-finding trial. Arthritis Rheum. 63, 1793–1803 (2011). · DOI
  66. Shevach, E. M. Immunology: regulating suppression. Science 322, 202–203 (2008). · DOI
  67. Lenschow, D. J. & Bluestone, J. A. T cell co-stimulation and in vivo tolerance. Curr. Opin. Immunol. 5, 747–752 (1993). · DOI
  68. Buch, M. H. et al. Mode of action of abatacept in rheumatoid arthritis patients having failed tumour necrosis factor blockade: a histological, gene expression and dynamic magnetic resonance imaging pilot study. Ann. Rheum. Dis. 68, 1220–1227 (2009). · DOI
  69. Ko, H. J. et al. CTLA4-Ig modifies dendritic cells from mice with collagen-induced arthritis to increase the CD4+CD25+Foxp3+ regulatory T cell population. J. Autoimmun. 34, 111–120 (2010). · DOI
  70. Choy, E. H. Selective modulation of T-cell co-stimulation: a novel mode of action for the treatment of rheumatoid arthritis. Clin. Exp. Rheumatol. 27, 510–518 (2009).
  71. Remans, P. H. et al. CTLA-4IG suppresses reactive oxygen species by preventing synovial adherent cell-induced inactivation of Rap1, a Ras family GTPASE mediator of oxidative stress in rheumatoid arthritis T cells. Arthritis Rheum. 54, 3135–3143 (2006). · DOI
  72. Alvarez-Quiroga, C. et al. CTLA-4-Ig therapy diminishes the frequency but enhances the function of TREG cells in patients with rheumatoid arthritis. J. Clin. Immunol. 31, 588–595 (2011). · DOI
  73. Platt, A. M. et al. Abatacept limits breach of self-tolerance in a murine model of arthritis via effects on the generation of T follicular helper cells. J. Immunol. 185, 1558–1567 (2010). · DOI
  74. Choy, E. H. et al. Repeat-cycle study of high-dose intravenous 4162W94 anti-CD4 humanized monoclonal antibody in rheumatoid arthritis. A randomized placebo-controlled trial. Rheumatology (Oxford) 41, 1142–1148 (2002). · DOI
  75. Yocum, D. E. et al. Clinical and immunologic effects of a PRIMATIZED anti-CD4 monoclonal antibody in active rheumatoid arthritis: results of a phase I, single dose, dose escalating trial. J. Rheumatol. 25, 1257–1262 (1998).
  76. Isaacs, J. D. Therapeutic T-cell manipulation in rheumatoid arthritis: past, present and future. Rheumatology 47, 1461–1468 (2008). · DOI
  77. O'Shea, J. J., Park, H., Pesu, M., Borie, D. & Changelian, P. New strategies for immunosuppression: interfering with cytokines by targeting the Jak/Stat pathway. Curr. Opin. Rheumatol. 17, 305–311 (2005). · DOI
  78. Ghoreschi, K., Laurence, A. & O'Shea, J. J. Janus kinases in immune cell signaling. Immunol. Rev. 228, 273–287 (2009). · DOI · Paper page
  79. Jiang, H. et al. Cytokine/Jak/Stat signaling mediates regeneration and homeostasis in the Drosophila midgut. Cell 137, 1343–1355 (2009). · DOI
  80. Fleischmann, R. Novel small-molecular therapeutics for rheumatoid arthritis. Curr. Opin. Rheumatol. 24, 335–341 (2012). · DOI
  81. O'Shea, J. J. & Murray, P. J. Cytokine signaling modules in inflammatory responses. Immunity. 28, 477–487 (2008). · DOI
  82. Burmester, G. R. et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet http://dx.doi.org/10.1016/S0140-6736(12)61424-X . · DOI
  83. Yoshida, H. et al. Low dose CP-690, 550 (tofacitinib), a pan-JAK inhibitor, accelerates the onset of experimental autoimmune encephalomyelitis by potentiating TH17 differentiation. Biochem. Biophys. Res. Commun. 418, 234–240 (2012). · DOI
  84. Sesin, C. A. & Bingham, C. O. 3rd. Remission in rheumatoid arthritis: wishful thinking or clinical reality? Semin. Arthritis Rheum. 35, 185–196 (2005). · DOI
  85. Katchamart, W. Predictors for remission in rheumatoid arthritis patients: a systematic review. Arthritis Care Res. 62, 1128–1143 (2010). · DOI
  86. Genovese, M. C. et al. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum. 50, 1412–1419 (2004). · DOI
  87. Weinblatt, M. et al. Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial. Ann. Rheum. Dis. 66, 228–234 (2007). · DOI
  88. Dépis, F. et al. Long term amelioration of established collagen-induced arthritis achieved with short term therapy combining anti-CD3 and anti-TNF treatments. Arthritis Rheum. 64, 3189–3198 (2012). · DOI

Cited by

Sorted by citations

Metadata

Authors
Choy, E. H., Kavanaugh, A. F., & Jones, S. A.
Venue
Nature Reviews Rheumatology
Publisher
Springer Science and Business Media LLC
Published
2013-02-19
Volume
9
Issue
3
Pages
154-163
ISSN
  • 1759-4790
  • 1759-4804
DOI
10.1038/nrrheum.2013.8
Cited by
141
References
3
Language
en
Licence
www.springer.com/tdm (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review